Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blautix in IBS-C and IBS-D
NCT03721107Phase 2Completed
- Sponsor
- 4D Pharma plc
- Start
- Oct 2018
- Primary completion
- May 2020
- Modality
- Live Biotherapeutic Products
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of blautix in irritable bowel syndrome (IBS) (4 cohorts), sponsored by 4D Pharma plc. Primary endpoint: Percentage of Participants With Overall Response at 8 weeks. Started Oct 2018; status: completed.
02
Drugs
blautix
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT03721107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03721107.